All In Biotech

Drug Trial Radar · NCT06580301

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Sep 25, 2024

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Interventions

  • YK012Drug

    The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence and Profile of Dose-limiting Toxicity (DLT)Time frame: 28 days after the first dose
  2. Maximum Tolerated dose (MTD) or The Recommended Dose for Future Clinical StudyTime frame: Through study completion, 20 weeks
  3. Number of Participants with Adverse EventsTime frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.
  4. Number of Participants with Serious Adverse EventsTime frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.
  5. Dose Expansion Phase: Objective Response Rate (ORR)Time frame: From the time the participant signs the ICF until hematological relapse, assessed up to 1 year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.